|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:ATCCode
|
gptkb:J05AR14
gptkb:J05AR15
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:CASNumber
|
1004316-88-4
|
|
gptkbp:component
|
gptkb:Symtuza
gptkb:Evotaz
gptkb:Genvoya
gptkb:Stribild
|
|
gptkbp:drugClass
|
CYP3A inhibitor
pharmacokinetic enhancer
inhibits CYP3A-mediated metabolism of coadministered drugs
|
|
gptkbp:eliminatedIn
|
renal
fecal
|
|
gptkbp:halfLife
|
3-4 hours
|
|
gptkbp:hasInChIKey
|
QMNWQGQMFQLOFV-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C40H53N7O5S2
|
|
gptkbp:hasPharmGKBID
|
PA162379255
|
|
gptkbp:hasSMILES
|
CC(C)CN(C(=O)NC(C(=O)NC1CCCN1C(=O)C(Cc2ccccc2)NC(=O)C3CC3)CSC4=NC5=CC=CC=C5S4)C6=CC=CC=C6
|
|
gptkbp:hasUNII
|
T1E1J9SG1G
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB06151
|
|
gptkbp:indication
|
pharmacokinetic enhancer for HIV therapy
|
|
gptkbp:KEGGID
|
D09741
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
CYP3A inhibitor
|
|
gptkbp:meltingPoint
|
~138°C
|
|
gptkbp:molecularWeight
|
776.0
|
|
gptkbp:name
|
gptkb:Cobicistat
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
98-99%
|
|
gptkbp:PubChem_CID
|
gptkb:DB06151
28536938
25154809
CHEMBL2107727
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
jaundice
rash
increased serum creatinine
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:GS-9350
|
|
gptkbp:target
|
gptkb:CYP3A5
gptkb:P-glycoprotein
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:bfsParent
|
gptkb:N-acetylcysteine
|
|
gptkbp:bfsLayer
|
6
|